Lyra Therapeutics appoints Harlan W. Waksal as Executive Chairman
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Subscribe To Our Newsletter & Stay Updated